Per-procedural Concentration of Direct Oral Anticoagulants (CORIDA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02643992|
Recruitment Status : Completed
First Posted : December 31, 2015
Last Update Posted : February 6, 2017
Background: Peri-procedural management of direct oral anticoagulants (DOAC) is challenging. The optimal duration of pre-procedural discontinuation that guarantees a minimal DOAC concentration ([DOAC]) at surgery is unknown. The usual 48-hour discontinuation might not be sufficient for all patients.
Objectives: To investigate the factors associated with per-procedural [DOAC]. To test the hypothesis that a 48-hour DOAC discontinuation is not sufficient to ensure a minimal perprocedural [DOAC], defined as [DOAC] < 30 ng/mL.
Methods: Patients treated with DOAC, and requiring any invasive procedure will be included in this multicentre, prospective, observational study. [DOAC], will be measured during invasive procedure.
|Condition or disease||Intervention/treatment|
|Per-procedural Concentrations of Oral Anticoagulants||Other: DOAC concentration measurement|
|Study Type :||Observational|
|Actual Enrollment :||270 participants|
|Study Start Date :||June 2013|
|Actual Primary Completion Date :||January 2016|
|Actual Study Completion Date :||January 2016|
- DOAC concentration [ Time Frame: beginning of invasive procedure ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02643992
|Fondation Ophtalmologique Adolphe de Rothschild (FOR)|
|Paris, France, 75019|